Brief: Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals

07/04/2025 12:41

April 7 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

RHYTHM PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 TRANSCEND TRIAL MEETS PRIMARY ENDPOINT WITH -19.8% PLACEBO-ADJUSTED BMI REDUCTION IN PATIENTS (N=120) WITH ACQUIRED HYPOTHALAMIC OBESITY

RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE THERAPY ACHIEVES -16.5% MEAN BMI CHANGE IN PATIENTS

RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE ACHIEVES -19.2% PLACEBO-ADJUSTED BMI REDUCTION IN ADULTS

RHYTHM PHARMACEUTICALS INC - REGULATORY SUBMISSIONS IN U.S. AND EU EXPECTED Q3 2025

RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH -16.5% MEAN BMI REDUCTION

RHYTHM PHARMACEUTICALS INC - NO NEW SAFETY SIGNALS OBSERVED WITH SETMELANOTIDE

Source text: ID:nGNX6NQcwV

Further company coverage: RYTM.O

 (((( Reuters.briefs@thomsonreuters.com ;));))